NASDAQ:CVAC CureVac (CVAC) Stock Price, News & Analysis → The new financial threat that could wipe out millions… (From InvestorPlace) (Ad) Free CVAC Stock Alerts $2.88 -0.11 (-3.68%) (As of 05:26 PM ET) Add Compare Share Share Today's Range$2.85▼$3.0050-Day Range$2.31▼$3.5152-Week Range$2.21▼$12.36Volume237,975 shsAverage Volume803,040 shsMarket Capitalization$644.77 millionP/E RatioN/ADividend YieldN/APrice Target$8.33 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get CureVac alerts: Email Address CureVac MarketRank™ Stock AnalysisAnalyst RatingHold2.00 Rating ScoreUpside/Downside189.4% Upside$8.33 Price TargetShort InterestHealthy4.57% of Float Sold ShortDividend StrengthN/ASustainability-1.88Upright™ Environmental ScoreNews Sentiment0.32Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.84) to ($0.60) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.64 out of 5 starsMedical Sector223rd out of 905 stocksPharmaceutical Preparations Industry92nd out of 422 stocks 3.0 Analyst's Opinion Consensus RatingCureVac has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 1 buy rating, 3 hold ratings, and 1 sell rating.Amount of Analyst CoverageCureVac has only been the subject of 3 research reports in the past 90 days.Read more about CureVac's stock forecast and price target. Previous Next 4.0 Short Interest Percentage of Shares Shorted4.57% of the float of CureVac has been sold short.Short Interest Ratio / Days to CoverCureVac has a short interest ratio ("days to cover") of 5.3.Change versus previous monthShort interest in CureVac has recently decreased by 16.37%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldCureVac does not currently pay a dividend.Dividend GrowthCureVac does not have a long track record of dividend growth. Previous Next 4.9 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreCureVac has received a 80.57% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "mRNA vaccines" and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for CureVac is -1.88. Previous Next 1.3 News and Social Media Coverage News SentimentCureVac has a news sentiment score of 0.32. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for CureVac this week, compared to 2 articles on an average week.MarketBeat FollowsOnly 2 people have added CureVac to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, CureVac insiders have not sold or bought any company stock.Percentage Held by InstitutionsOnly 17.26% of the stock of CureVac is held by institutions.Read more about CureVac's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for CureVac are expected to grow in the coming year, from ($0.84) to ($0.60) per share.Price to Book Value per Share RatioCureVac has a P/B Ratio of 1.15. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about CureVac's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Smallcaps DailyThe #1 Biotech Stock to Watch in 2024 is Attacking Viruses in a Unique WaySee how with its ongoing expansion and development of its diverse and promising product pipeline, this small-cap NYSE company is positioned to be a dominant and innovative leader in the nanomedicine and antiviral therapy space.Click to read About CureVac Stock (NASDAQ:CVAC)CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza. The company also develops CV8102, which is in Phase 1 clinical trial for treating melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CVGBM for treating cancer. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.Read More CVAC Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CVAC Stock News HeadlinesMay 3, 2024 | finance.yahoo.comSome Analysts Just Cut Their CureVac N.V. (NASDAQ:CVAC) EstimatesApril 29, 2024 | americanbankingnews.comBrokers Issue Forecasts for CureVac's Q1 2024 Earnings (NASDAQ:CVAC)May 8, 2024 | InvestorPlace (Ad)The new financial threat that could wipe out millions…During the Internet boom, companies like Pets.com were supposed to be promising investments riding the wave of a new tech boom. But then they were gone within a blink of an eye. One of the most successful investors in history just stepped forward to say the same thing is about to happen to AI stocks.April 27, 2024 | finance.yahoo.comCureVac Full Year 2023 Earnings: Misses ExpectationsApril 26, 2024 | seekingalpha.comCureVac N.V. (CVAC) Q4 2023 Earnings Call TranscriptApril 26, 2024 | investing.comCureVac appoints new Chief Business OfficerApril 26, 2024 | msn.comLeerink Partners Downgrades CureVac N.V. (CVAC)April 25, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: CureVac (CVAC) and BioMarin Pharmaceutical (BMRN)May 8, 2024 | InvestorPlace (Ad)The new financial threat that could wipe out millions…During the Internet boom, companies like Pets.com were supposed to be promising investments riding the wave of a new tech boom. But then they were gone within a blink of an eye. One of the most successful investors in history just stepped forward to say the same thing is about to happen to AI stocks.April 25, 2024 | finance.yahoo.comCureVac N.V. (NASDAQ:CVAC) Q4 2023 Earnings Call TranscriptApril 24, 2024 | markets.businessinsider.comEQS-News: CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2023 and Provides Business UpdateApril 24, 2024 | seekingalpha.comCureVac reports Q4 resultsApril 24, 2024 | seekingalpha.comCureVac N.V. 2023 Q4 - Results - Earnings Call PresentationApril 24, 2024 | finanznachrichten.deCureVac Announces Start of Combined Phase 1/2 Study in Avian Influenza ; Development in Collaboration with GSKApril 24, 2024 | msn.comCureVac BV reports Q4 resultsApril 24, 2024 | markets.businessinsider.comEQS-News: CureVac Announces Start of Combined Phase 1/2 Study in Avian Influenza (H5N1); Development in Collaboration with GSKApril 23, 2024 | finance.yahoo.comCureVac N.V. (NASDAQ:CVAC) stock most popular amongst private equity firms who own 31%, while individual investors hold 30%April 18, 2024 | markets.businessinsider.comCureVac (CVAC) Gets a Buy from Leerink PartnersApril 17, 2024 | markets.businessinsider.comEQS-News: CureVac and MD Anderson Enter Strategic Collaboration to Develop Novel Cancer VaccinesApril 16, 2024 | seekingalpha.comCureVac, MD Anderson team up for cancer vaccinesApril 16, 2024 | msn.comCureVac, MD Anderson teams up for cancer vaccinesApril 4, 2024 | msn.comCureVac, GSK Partner Release Data On Influenza Vaccine StudyApril 4, 2024 | markets.businessinsider.comEQS-News: CureVac Announces Promising Phase 2 Interim Data from Seasonal Influenza Vaccine Development Program in Collaboration with GSKMarch 25, 2024 | finance.yahoo.comCureVac N.V.: CureVac Provides Risk-Tolerant Investors With Pure-Play Exposure to mRNA CandidatesMarch 16, 2024 | finance.yahoo.comCVAC Oct 2024 7.500 callMarch 8, 2024 | seekingalpha.comCureVac: No Momentum In SightFebruary 1, 2024 | msn.comJimmy Kimmel Gives Trump A Brutal Reality Check On Just How Unpopular He IsSee More Headlines Receive CVAC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CureVac and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/29/2020Today5/08/2024Next Earnings (Estimated)6/04/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:CVAC CUSIPN/A CIK1809122 Webwww.curevac.com Phone49-70-71988-30Fax49-7071-9883Employees1,172Year FoundedN/APrice Target and Rating Average Stock Price Target$8.33 High Stock Price Target$13.00 Low Stock Price Target$4.00 Potential Upside/Downside+178.7%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-281,580,000.00 Net Margins-483.85% Pretax Margin-483.59% Return on Equity-41.87% Return on Assets-29.65% Debt Debt-to-Equity Ratio0.07 Current Ratio2.57 Quick Ratio2.43 Sales & Book Value Annual Sales$58.18 million Price / Sales11.51 Cash FlowN/A Price / Cash FlowN/A Book Value$2.50 per share Price / Book1.20Miscellaneous Outstanding Shares223,880,000Free FloatN/AMarket Cap$669.40 million OptionableOptionable Beta2.51 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesDr. Alexander Zehnder M.B.A. (Age 54)M.D., CEO, MD & Member of Management Board Comp: $1.05MMr. Pierre Kemula B.Sc. (Age 49)MD, CFO & Member of Management Board Comp: $700.97kDr. Malte Greune Ph.D. (Age 59)COO, Member of Management Board & MD Comp: $643.71kDr. Myriam Mendila M.D. (Age 58)Chief Development Officer, MD & Member of the Management Board Comp: $658.44kDr. Ulrike Gnad-Vogt M.D. (Age 51)Ph.D., Senior VP & Area Head of Oncology Comp: $304.47kDr. Sarah FakihVice President Corporate Communications & Investor RelationsMr. Marco Rau L.L.M.Ph.D., General CounselMr. Thorsten SchullerHead of Corporate CommunicationsSlavica Stevanovic-HeckHead of Human ResourcesDr. Patrick BaumhofSenior Vice President of TechnologyMore ExecutivesKey CompetitorsSilence TherapeuticsNASDAQ:SLNPhibro Animal HealthNASDAQ:PAHCORIC PharmaceuticalsNASDAQ:ORICLyell ImmunopharmaNASDAQ:LYELPharming GroupNASDAQ:PHARView All CompetitorsInstitutional OwnershipChina Universal Asset Management Co. Ltd.Bought 17,132 shares on 4/29/2024Ownership: 0.019%Ballentine Partners LLCBought 12,597 shares on 4/11/2024Ownership: 0.006%Platinum Investment Management Ltd.Bought 134,626 shares on 2/14/2024Ownership: 0.222%Aristides Capital LLCBought 23,777 shares on 2/13/2024Ownership: 0.011%Dynamic Technology Lab Private LtdBought 37,931 shares on 2/9/2024Ownership: 0.017%View All Institutional Transactions CVAC Stock Analysis - Frequently Asked Questions Should I buy or sell CureVac stock right now? 5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for CureVac in the last twelve months. There are currently 1 sell rating, 3 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" CVAC shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CVAC, but not buy additional shares or sell existing shares. View CVAC analyst ratings or view top-rated stocks. What is CureVac's stock price target for 2024? 5 brokerages have issued 12 month price targets for CureVac's shares. Their CVAC share price targets range from $4.00 to $13.00. On average, they predict the company's share price to reach $8.33 in the next twelve months. This suggests a possible upside of 189.4% from the stock's current price. View analysts price targets for CVAC or view top-rated stocks among Wall Street analysts. How have CVAC shares performed in 2024? CureVac's stock was trading at $4.21 at the beginning of 2024. Since then, CVAC stock has decreased by 31.6% and is now trading at $2.88. View the best growth stocks for 2024 here. Are investors shorting CureVac? CureVac saw a decrease in short interest in the month of April. As of April 15th, there was short interest totaling 4,190,000 shares, a decrease of 16.4% from the March 31st total of 5,010,000 shares. Based on an average trading volume of 783,900 shares, the days-to-cover ratio is presently 5.3 days. Currently, 4.6% of the shares of the stock are sold short. View CureVac's Short Interest. When is CureVac's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, June 4th 2024. View our CVAC earnings forecast. How were CureVac's earnings last quarter? CureVac (NASDAQ:CVAC) announced its earnings results on Sunday, November, 29th. The company reported ($0.24) EPS for the quarter, beating analysts' consensus estimates of ($54.37) by $54.13. CureVac had a negative net margin of 483.85% and a negative trailing twelve-month return on equity of 41.87%. What ETFs hold CureVac's stock? ETFs with the largest weight of CureVac (NASDAQ:CVAC) stock in their portfolio include Morningstar US Small Growth (MSGR).Amplify Treatments, Testing and Advancements ETF (GERM). What other stocks do shareholders of CureVac own? Based on aggregate information from My MarketBeat watchlists, some companies that other CureVac investors own include Moderna (MRNA), Tesla (TSLA), Novavax (NVAX), Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), Pfizer (PFE), Johnson & Johnson (JNJ), Zoom Video Communications (ZM) and NIO (NIO). When did CureVac IPO? CureVac (CVAC) raised $200 million in an initial public offering (IPO) on Friday, August 14th 2020. The company issued 13,300,000 shares at $14.00-$16.00 per share. BofA Securities, Jefferies and Credit Suisse acted as the underwriters for the IPO and Berenberg and Kempen were co-managers. Who are CureVac's major shareholders? CureVac's stock is owned by many different retail and institutional investors. Top institutional investors include China Universal Asset Management Co. Ltd. (0.02%), Ballentine Partners LLC (0.01%) and Concourse Financial Group Securities Inc. (0.00%). How do I buy shares of CureVac? Shares of CVAC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CVAC) was last updated on 5/8/2024 by MarketBeat.com Staff From Our PartnersThe #1 Biotech Stock to Watch in 2024 is Attacking Viruses in a Unique WaySmallcaps DailyElon Musk Secret Crypto Plot ExposedCrypto 101 MediaAI “wealth window” is closing June 25thParadigm PressShocking: One AI startup's revenue could surge 4,735%Manward PressForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingGold Set to EXPLODE!Gold Safe ExchangeCharles Payne Demystifies OptionsUnstoppable ProsperityThe AI Stock that’s Disrupting Every IndustryStockEarnings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CureVac Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
